Drugs / intravenous immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03174964 | Jul 2016 → Feb 2017 | infertility disorder | Tabriz University of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intravenous immunoglobulin | “In previous years, followed by the production of intravenous immunoglobulin (IVIg) and determine its effect on immune suppression, IVIg uses for the treatment of various diseases” NCT03174964 ↗ |
| Known as | IVIg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03174964 ↗ |
| Action | Inhibit | “Probably one of the mechanisms of IVIg is its effect in suppressing the activity of NK cells.” NCT03174964 ↗ |
| Modality | Protein / enzyme biologic | “intravenous immunoglobulin (IVIg)” NCT03174964 ↗ |
| Route | Intravenous | “massive intravenous immunoglobulin (MIVIg) treatment” PMID 12765346 ↗ Feb 2003 |